[Remdesivir (COVID-19, without supplemental oxygen, increased risk of progressing to severe COVID-19, ≥ 4 weeks, 3 to < 40 kg) - Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018014622
German
Original Title: Remdesivir (COVID-19, ohne zusätzliche Sauerstoffzufuhr, erhöhtes Risiko für schweren Verlauf, ≥ 4 Wochen, 3 kg bis < 40 kg)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a25-92.html
Year Published: 2025
URL for published report: https://www.iqwig.de/download/a25-92_remdesivir_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A25-92
MeSH Terms
  • COVID-19
  • COVID-19 Drug Treatment
  • SARS-CoV-2
  • Coronavirus Infections
  • Child, Preschool
  • Infant
Keywords
  • Remdesivir
  • COVID-19
  • Infant
  • Child – Preschool
  • Child
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.